pimagedine has been researched along with Asymmetric Diabetic Proximal Motor Neuropathy in 17 studies
pimagedine: diamine oxidase & nitric oxide synthase inhibitor; an advanced glycosylation end product inhibitor; used in the treatment of diabetic complications; structure
aminoguanidine : A one-carbon compound whose unique structure renders it capable of acting as a derivative of hydrazine, guanidine or formamide.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We examined the ability of a pyridoxal-aminoguanidine adduct with both antiglycation and antioxidant activities in vitro to protect against neuropathy and cataract in streptozotocin-diabetic rats and compared the result with that of aminoguanidine." | 7.72 | Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. ( Chen, AS; Kamei, A; Miwa, I; Sugiura, M; Taguchi, T; Wakasugi, Y; Wang, MW, 2004) |
| "We examined the ability of a pyridoxal-aminoguanidine adduct with both antiglycation and antioxidant activities in vitro to protect against neuropathy and cataract in streptozotocin-diabetic rats and compared the result with that of aminoguanidine." | 3.72 | Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats. ( Chen, AS; Kamei, A; Miwa, I; Sugiura, M; Taguchi, T; Wakasugi, Y; Wang, MW, 2004) |
| "Insulin sensitivity was measured using the insulin tolerance test (ITT), both in STZ diabetic and in Zucker diabetic fatty (ZDF) rats (model of type 2 diabetes)." | 1.31 | Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models. ( Bíró, K; Jednákovits, A; Kukorelli, T; Kürthy, M; Mogyorósi, T; Nagy, K; Tálosi, L, 2002) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (52.94) | 18.2507 |
| 2000's | 8 (47.06) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Uesaka, Y | 1 |
| Guo, SS | 1 |
| Tang, DY | 1 |
| Liang, XC | 1 |
| Miyata, T | 1 |
| Kurokawa, K | 1 |
| Chen, AS | 1 |
| Taguchi, T | 1 |
| Sugiura, M | 1 |
| Wakasugi, Y | 1 |
| Kamei, A | 1 |
| Wang, MW | 1 |
| Miwa, I | 1 |
| Cameron, NE | 2 |
| Gibson, TM | 1 |
| Nangle, MR | 1 |
| Cotter, MA | 2 |
| Shotton, HR | 1 |
| Adams, A | 1 |
| Lincoln, J | 1 |
| Monnier, V | 1 |
| Gries, FA | 1 |
| Schmidt, RE | 1 |
| Dorsey, DA | 1 |
| Beaudet, LN | 1 |
| Reiser, KM | 1 |
| Williamson, JR | 1 |
| Tilton, RG | 1 |
| Monnier, VM | 1 |
| Yildiz, O | 1 |
| Ozata, M | 1 |
| Ozkardeş, A | 1 |
| Deniz, G | 1 |
| Yildirimkaya, M | 1 |
| Corakçi, A | 1 |
| Yardim, M | 1 |
| Gündoğan, MA | 1 |
| Ino-ue, M | 1 |
| Ohgiya, N | 1 |
| Yamamoto, M | 1 |
| Vinik, AI | 1 |
| Park, TS | 1 |
| Stansberry, KB | 1 |
| Pittenger, GL | 1 |
| Kürthy, M | 1 |
| Mogyorósi, T | 1 |
| Nagy, K | 1 |
| Kukorelli, T | 1 |
| Jednákovits, A | 1 |
| Tálosi, L | 1 |
| Bíró, K | 1 |
| Yagihashi, S | 1 |
| Kamijo, M | 1 |
| Baba, M | 1 |
| Yagihashi, N | 1 |
| Nagai, K | 1 |
| Kihara, M | 1 |
| Schmelzer, JD | 1 |
| Poduslo, JF | 1 |
| Curran, GL | 1 |
| Nickander, KK | 1 |
| Low, PA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Dose Ranging Safety and Pharmacokinetics Study of Arimoclomol in Amyotrophic Lateral Sclerosis (ALS)[NCT00244244] | Phase 2 | 80 participants | Interventional | 2005-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
6 reviews available for pimagedine and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
[Prevention and treatment of diabetic neuropathy].
Topics: Aldehyde Reductase; Angiotensin-Converting Enzyme Inhibitors; Antioxidants; Chronic Disease; Diabeti | 2002 |
A detective story for biomedical footprints towards new therapeutic interventions in diabetic nephropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Glycation End Products, Advanced; G | 2003 |
Inhibitors of advanced glycation end product formation and neurovascular dysfunction in experimental diabetes.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Diabetic Neuropathies; Glycation En | 2005 |
[Non-enzymatic glycosylation of proteins. Complications of diabetes mellitus, aging and kidney failure].
Topics: Aging; Arginine; Blood Glucose; Diabetes Mellitus; Diabetic Neuropathies; Glycation End Products, Ad | 1993 |
Alternative therapeutic principles in the prevention of microvascular and neuropathic complications.
Topics: Aldehyde Reductase; Antioxidants; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Neuropa | 1995 |
Diabetic neuropathies.
Topics: Aldehyde Reductase; Animals; Diabetic Neuropathies; Enzyme Inhibitors; gamma-Linolenic Acid; Guanidi | 2000 |
11 other studies available for pimagedine and Asymmetric Diabetic Proximal Motor Neuropathy
| Article | Year |
|---|---|
[Effect of wenjingtong composita on blood glucose and advanced glycosylation end products in sciatic nerve of streptozotocin-induced diabetic rats].
Topics: Animals; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Drugs, Chinese Herba | 2002 |
Pyridoxal-aminoguanidine adduct is more effective than aminoguanidine in preventing neuropathy and cataract in diabetic rats.
Topics: 8-Hydroxy-2'-Deoxyguanosine; Animals; Cataract; Deoxyguanosine; Diabetes Mellitus, Experimental; Dia | 2004 |
Effect of aminoguanidine treatment on diabetes-induced changes in the myenteric plexus of rat ileum.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzyme Inhibitors; Guanidines; Ileu | 2007 |
Effect of aminoguanidine on the frequency of neuroaxonal dystrophy in the superior mesenteric sympathetic autonomic ganglia of rats with streptozocin-induced diabetes.
Topics: Animals; Axons; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzyme Inhibitors; Ganglia, | 1996 |
Aminoguanidine and diabetic neuropathy.
Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Guanidines; Motor Neurons; Neural C | 1996 |
Rapid reversal by aminoguanidine of the neurovascular effects of diabetes in rats: modulation by nitric oxide synthase inhibition.
Topics: Animals; Arginine; Blood Glucose; Blood Pressure; Diabetes Mellitus, Experimental; Diabetic Angiopat | 1996 |
Comparison of the effects of aminoguanidine and L-carnitine treatments on somatosensorial evoked potentials in alloxan-diabetic rats.
Topics: Alloxan; Animals; Blood Glucose; Body Weight; Carnitine; Diabetes Mellitus, Experimental; Diabetic N | 1996 |
Effect of aminoguanidine on optic nerve involvement in experimental diabetic rats.
Topics: Animals; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Dose-Response Relation | 1998 |
Effect of BRX-220 against peripheral neuropathy and insulin resistance in diabetic rat models.
Topics: Animals; Diabetic Neuropathies; Guanidines; Hydroxylamines; Hypoglycemic Agents; Insulin Resistance; | 2002 |
Effect of aminoguanidine on functional and structural abnormalities in peripheral nerve of STZ-induced diabetic rats.
Topics: Animals; Blood Glucose; Body Weight; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Glycate | 1992 |
Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals.
Topics: Action Potentials; Animals; Capillary Permeability; Diabetes Mellitus, Experimental; Diabetic Neurop | 1991 |